Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for σ receptors

Psychopharmacology

Volumn 145, Issue 3, 1999, Pages 295-302

  Takahashi, S ^a   Sonehara, K ^a   Takagi, K ^a   Miwa, T ^a   Horikomi, K ^a   Mita, N ^b   Nagase, H ^b   Iizuka, K ^b   Sakai, K ^b  

^a Mitsui Pharmaceuticals Inc   (Japan)

^b MITSUI CHEMICALS INC   (Japan)

Author keywords

Receptor; Antipsychotic; Haloperidol; Head weaving behavior; MS 377; Sultopride Risperidone

Indexed keywords

1 (4 CHLOROPHENYL) 3 [4 (2 METHOXYETHYL)PIPERAZIN 1 YL]METHYL 2 PYRROLIDINONE LEVO TARTARIC ACID; APOMORPHINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; FANANSERIN; HALOPERIDOL; N ALLYLNORMETAZOCINE; NEUROLEPTIC AGENT; NIALAMIDE; PENTAZOCINE; PHENCYCLIDINE; RISPERIDONE; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SIGMA 1 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR; SPIPERONE; SULTOPRIDE; TARTARIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; CATALEPSY; DOPAMINE AGONISTS; FREE RADICAL SCAVENGERS; GUINEA PIGS; HALOPERIDOL; HEAD MOVEMENTS; MALE; MICE; PHENAZOCINE; PHENCYCLIDINE; PIPERAZINES; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; RECEPTORS, SIGMA; RISPERIDONE; SEROTONIN; SEROTONIN ANTAGONISTS; STEREOTYPED BEHAVIOR; SULPIRIDE; TARTRATES;

EID: 0032784317     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130051061     Document Type: Article

References (37)

1. Akunne HC, Whetzel SZ, Wiley JN, Corbin AE, Ninteman FW, Tecle H, Pei Y, Pugsley TA, Heffner TG (1997) The pharmacology of the novel and selective sigma ligand, PD 144418. Neuropharmacology 36:51-62
2. Bowen WD, Walker JM, De Costa BR, Wu R, Tolentino PJ, Finn D, Rothman RB, Rice KC (1992) Characterization of the enantiomers of cis-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl) cyclohexylamine (BD737 and BD738): novel compounds with high affinity, selectivity and biological efficacy at sigma receptors. J Pharmacol Exp Ther 262:32-40
3. Burt DR, Enna SJ, Creese I, Snyder SH (1975) Dopamine receptor binding in the corpus striatum of mammalian brain. Proc Natl Acad Sci USA 72:4655-4659
4. Cook L, Tam SW, Rohrbach KW (1992) DuP 734 [1-(cyclopropylmethyl)-4-(2′(4″-fluorophenyl)-2′-oxoethyl)-piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects. J Pharmacol Exp Ther 263:1159-1166
5. Costall B, Naylor RJ, Olley LE (1972) The substantia nigra and stereotyped behavior. Eur J Pharmacol 18:95-106
6. Eyles DW, Whiteford HA, Stedman TJ, Pond SM (1992) Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol. Psychopharmacology 106:268-274
7. Freeman AS, Bunney BS (1984) The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur J Pharmacol 104:287-293
8. Frieboes RM, Murck H, Wiedemann K, Holsboer F, Steiger A (1997) Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology 132:82-88
9. Gundlach AL, Largent BL, Snyder SH (1985) Phencyclidine and G opiate receptors in brain: biochemical and autoradiographical differentiation. Eur J Pharmacol 113:465-466
10. 3H-3-(hydroxyphenyl)-N-(1-propyl)piperidine. J Neurosci 6:1757-1770
11. 1-binding site. Proc Natl Acad Sci USA 93:8072-8077
12. 2A receptors in rat brain by subchronic administration of σ receptor ligand NE-100. Life Sci 24:2245-2254
13. 4 sites in schizophrenic brains. Eur J Pharmacol 314:R3-R5
14. Hepler D, Tam SW, De Noble VJ (1988) Selective PCP and sigma receptor agonists produced differential effects in rats with unilateral lesions in the substantia nigra. Soc Neurosci Abstr 14:806
15. Javitt DC (1987) Negative schizophrenic and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 9:12-35
16. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308
17. 1 receptors in amelioration of conditioned fear stress in rat: association with mesolimbic dopaminergic systems. Eur J Pharmacol 319:165-172
18. 2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21:301-314
19. Martin WR, Eades CG, Thompson JA, Kuppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532
20. Matthews RT, Mcmillen BA, Sallis R, Blair D (1986) Effects of BMY 14802 a potential antipsychotic drug, on rat brain dopaminergic function. J Pharmacol Exp Ther 239:124-141
21. Meltzer HY, Lee MA, Ranjan R (1994) Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand 90: 95-101
22. Modell S, Naber D, Holzbach R (1996) Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study. Pharmacopsychiatry 29:63-66
23. Okuyama S, Imagawa Y, Ogawa S, Araki H, Ajima A, Tanaka M, Muramatu M, Nakazato A, Yamaguchi K, Yoshida M, Otomo S (1993) NE-100, a novel sigma receptor ligand: in vivo tests. Life Sci 53:285-290
24. Quirion R, Chicheportiche R, Contreras PC, Johnson KM, Lodge D, Tam SW, Woods JH, Zukin SR (1987) Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci 10:444-446
25. Seth P, Fei YJ, Li HW, Huang W, Leibach FH, Ganapathy V (1998) Cloning and functional characterization of a σ receptor from rat brain. J Neurochem 70:922-931
26. Shirayama Y, Nishikawa N, Umino A, Takahashi K (1993) p-Chlorophenylalanine-reversible reduction of σ binding sites by chronic imipramine treatment in rat brain. Eur J Pharmacol 237:117-126
27. Steinfels GF, Tam SW (1989) Selective σ receptor agonist and antagonist affect dopamine neuronal activity. Eur J Pharmacol 163:167-170
28. Steinfels GF, Tam SW, Cook L (1989) Electrophysiological effects of selective σ-receptor agonists, antagonists, and the selective phencyclidine receptor agonist MK-801 on midbrain dopamine neurons. Neuropsychopharmacology 2:201-209
29. Takahashi S, Miwa T, Horikomi K, Mita N, Nagase H, Iizuka H, Oguchi T, Sakai K (1997) Pharmacological studies of MS-355, a novel antipsychotic drug. Jpn J Psychopharmacol 17:304
30. 3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 81:5618-5621
31. 2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles. J Pharmacol Exp Ther 263: 1167-1174
32. Tarsey D (1983) Neuroleptic-induced extrapyramidal reactions; classification, description and diagnosis. Clin Neuropharmacol 6:S9-S26
33. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:407-418
34. Vilner BJ, Bowen WD (1992) Characterization of sigma like binding sites of NB41A3, S-20Y, and N1E-115 neuroblastomas, C6 glioma, and NG108-15 neuroblastoma-glioma hybrid cells: further evidence for sigma-2 receptors. In: Kamenka JM, Domino EF (eds) Multiple sigma and PCP receptors ligands: mechanisms for neuromodulation and neuroprotection? Npp Books, pp 341-353
35. Weiser SD, Patrick SL, Mascarella SW, Jeannette DP, Bai X, Carroll FI, Walker JM, Patrick RL (1995) Stimulation of rat striatal tyrosine hydroxylase activity following intranigral administration of σ receptor ligands. Eur J Pharmacol 275:1-7
36. Wyrick SD, Booth RG (1995) Progress in sigma receptor research. Drugs Future 20:1033-1044
37. 3H]cyclazocine binding to multiple receptor sites. Mol Pharmacol 20:246-254